Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Summit Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.summittxinc.com/...
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Robert William Duggan; Mahkam Zanganeh, DDS, MBA
Number Of Employees: 159
Enterprise Value: $12,416,924,489
PE Ratio: -56.44
Exchange/Ticker 1: NASDAQ:SMMT
Exchange/Ticker 2: N/A
Latest Market Cap: $13,948,508,160
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 22, 2025
Finance
2025 Biotech Preview: Markets, Catalysts and AI
Assessing the bull and bear arguments and the catalysts for biotech in the New Year
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Nov 19, 2024
Politics, Policy & Law
RFK Jr. & HHS, Blenrep’s comeback, China deals: a BioCentury podcast
One editor’s take on why a Kennedy-led HHS would be disastrous for FDA, biopharma and patients
BioCentury | Nov 14, 2024
Deals
More BD in Akeso’s wake: Merck buys into LaNova’s bispecific for $588M up front
Marketer of Keytruda takes rights to bifunctional molecule in class that could compete directly with its top seller
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Nov 14, 2024
Deals
Already partners on bispecific, BioNTech buys Biotheus for $800M
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
BioCentury | Nov 6, 2024
Deals
Dealmaking in a drought crowns Gracell, Proteologix BayHelix winners
M&A and licensing deals feature prominently in nearly all categories of this year’s BayHelix Awards
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
Items per page:
1 - 10 of 56